Loading
Nanoparticle-based Drug Delivery / Nanoplatforms for Cancer Theranostics / Photoacoustic and Ultrasonic Imaging · Journal article
Pharmaceutics · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical study describing design, synthesis, and characterization of A2S-TT nanoparticles as a dual-modality (NIR-II/photoacoustic) imaging platform for photodynamic therapy in triple-negative breast cancer models. In vitro and in vivo studies in tumor-bearing mice show ROS generation, tumor accumulation, and tumor suppression under 808 nm laser irradiation without comparative efficacy data against standard therapies or quantitative tumor growth inhibition metrics.
Uncontrolled preclinical study (in vitro and in vivo). Triple-negative breast cancer cell lines and immunocompetent or immunodeficient mice bearing TNBC xenografts; specific cell lines, mouse strains, tumor size at treatment, and animal numbers not stated. Intervention: A2S-TT nanoparticles administered with 808 nm laser irradiation for photodynamic therapy. Not stated.
A2S-TT NPs generated reactive oxygen species under 808 nm laser excitation at tumor sites, inducing mitochondrial membrane potential disruption and DNA damage leading to apoptosis In vitro: A2S-TT NPs showed minimal cytotoxicity without light exposure but significantly enhanced tumor cell killing under laser irradiation In vivo: A2S-TT NPs accumulated at tumor sites, enabled dual-modal imaging visualization, and exhibited tumor-suppressive effects while avoiding significant normal tissue damage
In vivo safety assessed descriptively ('minimal systemic toxicity'); no pharmacokinetics, biodistribution kinetics, or organ toxicity metrics provided In vitro: A2S-TT NPs showed minimal cytotoxicity without light exposure but significantly enhanced tumor cell killing under laser irradiation
This work describes an early-stage nanoparticle platform with potential clinical application, but lacks quantitative efficacy data, comparator arms, pharmacokinetics, toxicology, or dose-escalation studies needed to guide translation to human trials. Clinicians should await phase 1 data and comparative effectiveness studies before considering clinical relevance.
Preclinical proof-of-concept study in cell and mouse models of a novel nanoparticle platform; no human data, efficacy metrics lack quantitative comparison to standard therapy, and no phase 1 translation reported.
As stated by the source record.
This work describes an early-stage nanoparticle platform with potential clinical application, but lacks quantitative efficacy data, comparator arms, pharmacokinetics, toxicology, or dose-escalation studies needed to guide translation to human trials. Clinicians should await phase 1 data and comparative effectiveness studies before considering clinical relevance.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Background: Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer characterized by significant treatment challenges and poor prognosis. Traditional therapies such as surgical resection, radiotherapy, and chemotherapy often suffer from limitations including insufficient therapeutic specificity, potential damage to normal tissues, and limited imaging capability. The integrated diag{Pareja, 2018 #13}nosis-treatment platform combines diagnostic and therapeutic functions, offering a novel approach for real-time tumor monitoring and precision therapy. Methods: Accordingly, this study designed and developed an integrated diagnostic and therapeutic platform called A2S-TT NPs, utilizing self-assembled nanoparticles incorporating organic conjugated molecules for precise photodynamic therapy (PDT) guided by dual modalities of Near-infrared II (NIR-II) fluorescence imaging and photoacoustic imaging (PA). Results: Under 808 nm laser excitation, A2S-TT NPs efficiently generated reactive oxygen species (ROS) at the tumor site, inducing mitochondrial membrane potential disruption and DNA damage to activate apoptosis. In vitro experiments demonstrated that A2S-TT NPs exhibited intense NIR-II fluorescence and photoacoustic signals, showcasing excellent dual-modal imaging potential. Moreover, it demonstrated minimal cytotoxicity in the absence of light exposure but significantly enhanced tumor cell killing under laser irradiation, demonstrating superior biosafety and photodynamic efficacy. In vivo studies further confirmed that A2S-TT NPs effectively accumulated at tumor sites, enabling visualization-based monitoring through its mediated NIR-II and PA dual-modal imaging. Additionally, A2S-TT NPs-mediated PDT exhibited remarkable tumor-suppressive effects while avoiding significant damage to normal tissues. Discussion: This study constructs a novel PA/NIR-II dual-modal imaging-guided PDT platform based on donor–acceptor conjugated polymer A2S-TT NPs for integrated TNBC theranostics. PA provides high-resolution deep-tissue imaging, while NIR-II fluorescence offers high sensitivity and deep penetration; their complementary strengths support precise tumor localization and real-time therapeutic monitoring. Under dual-modal guidance, A2S-TT NPs enrich in tumors and generate abundant ROS upon 808 nm laser irradiation to boost PDT efficacy. In vitro and in vivo biosafety tests confirm its favorable biocompatibility with minimal systemic toxicity at therapeutic doses. Conclusions: In conclusion, A2S-TT NPs achieved precise, efficient, safe, and controllable PDT through dual-mode imaging using NIR-II and PA, providing a novel strategy with clinical translation potential for the integrated diagnosis and treatment of TNBC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.